Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4313003 | 0.95 | TLR8 (0.46) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL4308938 | 0.94 | TLR8 (0.47) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL4319537 | 0.93 | TLR8 (0.48) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL8326936 | 0.93 | TLR8 (0.53) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL3168166 | 0.93 | TLR8 (0.46) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL4792464 | 0.92 | TLR7 (0.48) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL6723768 | 0.91 | TLR8 (0.48) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL4793161 | 0.90 | TLR8 (0.50) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL4317829 | 0.90 | TLR8 (0.46) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL5616943 | 0.89 | TLR8 (0.46) | TLR8TLR7NUDT1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112677-B2 | 1H-imidazo dimers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1542688-A2 | 1H-IMIDAZO DIMERS | 3M Innovative Properties Company (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050026947-A1 | 1H-imidazo dimers | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-03 | — | — | US | disclosed |
| US-6818650-B2 | 1H-IMIDAZO(4,5-C)- QUINOLINE OR -PYRIDINE DERIVATIVES; INDUCE BIOSYNTHESIS OF CYTOKINES; VIRAL DISEASES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; IMMUNOMODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-16 | — | — | US | disclosed |
| US-20040132766-A1 | 1H-imidazo dimers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| WO-2004028539-A2 | 1H-IMIDAZO DIMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026947-A1 | 1H-imidazo dimers | IL2, EIF2AK2, IRF3 | TLR8 176/4885TLR7 173/4885NUDT1 1332/4885 |
| US-20040132766-A1 | 1H-imidazo dimers | IL2, EIF2AK2, IRF3 | TLR8 176/4885TLR7 173/4885NUDT1 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.